Metropolis Healthcare Ltd
Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.
- Market Cap ₹ 11,608 Cr.
- Current Price ₹ 560
- High / Low ₹ 575 / 397
- Stock P/E 66.4
- Book Value ₹ 69.1
- Dividend Yield 0.18 %
- ROCE 14.7 %
- ROE 11.5 %
- Face Value ₹ 2.00
Pros
Cons
- Stock is trading at 8.10 times its book value
- The company has delivered a poor sales growth of 9.22% over past five years.
- Company has a low return on equity of 12.8% over last 3 years.
- Dividend payout has been low at 14.9% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 388 | 456 | 475 | 545 | 647 | 761 | 856 | 998 | 1,228 | 1,148 | 1,208 | 1,331 | 1,566 | |
| 285 | 339 | 359 | 405 | 467 | 559 | 619 | 708 | 880 | 855 | 920 | 1,023 | 1,211 | |
| Operating Profit | 104 | 117 | 116 | 140 | 181 | 203 | 237 | 290 | 348 | 293 | 288 | 308 | 355 |
| OPM % | 27% | 26% | 24% | 26% | 28% | 27% | 28% | 29% | 28% | 26% | 24% | 23% | 23% |
| 10 | 7 | 29 | 39 | 6 | 8 | -17 | 12 | 34 | 15 | 9 | 15 | 15 | |
| Interest | 3 | 2 | 2 | 2 | 4 | 4 | 13 | 12 | 25 | 32 | 28 | 24 | 21 |
| Depreciation | 16 | 21 | 17 | 17 | 19 | 20 | 39 | 46 | 63 | 89 | 94 | 109 | 124 |
| Profit before tax | 95 | 101 | 128 | 160 | 164 | 187 | 169 | 244 | 293 | 188 | 175 | 191 | 225 |
| Tax % | 34% | 33% | 36% | 33% | 32% | 34% | 24% | 25% | 27% | 24% | 26% | 24% | |
| 63 | 68 | 82 | 107 | 112 | 124 | 128 | 183 | 215 | 143 | 128 | 146 | 169 | |
| EPS in Rs | 14.32 | 15.44 | 20.10 | 26.61 | 27.29 | 5.99 | 6.29 | 8.95 | 10.46 | 6.98 | 6.24 | 7.00 | 8.12 |
| Dividend Payout % | 2% | 0% | 100% | 49% | 0% | 55% | 32% | 22% | 19% | 29% | 16% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 9% |
| 3 Years: | 3% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -1% |
| 3 Years: | -12% |
| TTM: | 15% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | 18% |
| 1 Year: | 31% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 17% |
| 3 Years: | 13% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 292 | 352 | 269 | 314 | 405 | 408 | 513 | 696 | 876 | 978 | 1,086 | 1,321 | 1,422 |
| 20 | 14 | 5 | 1 | 1 | 18 | 67 | 112 | 379 | 266 | 197 | 204 | 201 | |
| 69 | 87 | 107 | 188 | 110 | 113 | 160 | 181 | 256 | 240 | 254 | 324 | 359 | |
| Total Liabilities | 391 | 462 | 391 | 512 | 526 | 550 | 750 | 1,000 | 1,521 | 1,495 | 1,547 | 1,859 | 1,993 |
| 149 | 153 | 142 | 202 | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 | 1,447 | 1,573 | |
| CWIP | 1 | 0 | 1 | 1 | 0 | 6 | 3 | 0 | 6 | 20 | 0 | 0 | 0 |
| Investments | 132 | 168 | 101 | 142 | 102 | 33 | 14 | 10 | 16 | 15 | 55 | 71 | 21 |
| 109 | 141 | 147 | 167 | 216 | 298 | 437 | 647 | 440 | 340 | 316 | 341 | 399 | |
| Total Assets | 391 | 462 | 391 | 512 | 526 | 550 | 750 | 1,000 | 1,521 | 1,495 | 1,547 | 1,859 | 1,993 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77 | 69 | 91 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 | 263 | |
| -61 | -56 | 96 | -86 | 1 | 36 | -104 | 63 | -736 | 48 | -89 | -199 | |
| -14 | -9 | -174 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 | -87 | |
| Net Cash Flow | 2 | 4 | 14 | -1 | 18 | 8 | 56 | 279 | -321 | 3 | -6 | -23 |
| Free Cash Flow | 53 | 46 | 79 | 45 | 90 | 67 | 179 | 221 | 223 | 195 | 200 | 196 |
| CFO/OP | 103% | 87% | 113% | 109% | 89% | 78% | 118% | 106% | 96% | 102% | 105% | 99% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 57 | 54 | 54 | 57 | 66 | 55 | 45 | 40 | 39 | 38 | 41 |
| Inventory Days | 47 | 52 | 46 | 38 | 53 | 55 | 44 | 59 | 68 | 64 | 58 | 65 |
| Days Payable | 75 | 92 | 96 | 97 | 88 | 90 | 152 | 160 | 136 | 136 | 150 | 171 |
| Cash Conversion Cycle | 19 | 17 | 3 | -5 | 21 | 30 | -54 | -56 | -29 | -33 | -53 | -65 |
| Working Capital Days | 22 | 32 | 8 | -27 | 28 | 33 | 2 | -9 | -26 | -22 | -16 | -18 |
| ROCE % | 28% | 34% | 46% | 43% | 43% | 40% | 36% | 29% | 17% | 16% | 15% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Laboratories Number |
|
|||||||||
| Number of Patient Visits (Millions) Millions |
||||||||||
| Number of Tests Conducted (Millions) Millions |
||||||||||
| Service Network points (Collection Centers/PSCs/ARCs) Number |
||||||||||
| Revenue Per Patient (RPP) INR |
||||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8 May
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
7 May - Company will participate in the Q4 FY26 earnings conference call (i.e. post earnings/quarterly call), organized by Ambit Capital on Thursday, May 14, 2026 at 09:00 …
-
Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended March 31, 2026 And Declaration Of 2Nd Interim Dividend, If Any, For The Financial Year 2025-26
7 May - Board to meet on May 13, 2026, to approve FY26 audited results and consider 2nd interim dividend.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026
Annual reports
Concalls
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Oct 2025TranscriptAI SummaryPPT
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Dec 2024Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021Transcript PPT
-
Nov 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
May 2020Transcript PPT
-
Mar 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Nov 2019TranscriptAI SummaryPPT
-
Sep 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
Aug 2019TranscriptAI SummaryPPT
-
Jul 2019TranscriptAI SummaryPPT
-
Jul 2019TranscriptAI SummaryPPT
-
May 2019Transcript PPT
Leading Diagnostics company[1] Metropolis Healthcare Ltd is the second largest Diagnostic company in India and the largest player in Western and Southern India.